Faeth Therapeutics
NASDAQ: FTHAustin, US · Delaware corporation · 11 known investors
Faeth Therapeutics develops PIKTOR, an oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway for cancer treatment, currently in clinical trials for endometrial and breast cancer.
Founders & leadership
AP
Anand ParikhExecutive Officer, Director, Promoter
OM
Oliver MaddocksExecutive Officer, Director
AM
Alex MorganDirector
JD
Jayson DallasDirector
RG
Robert GouldDirector
SH
Stephen HahnDirector
Investors · 11
Cota CapitalSan Francisco
Future VenturesLos Altos · $1M – $10M
iSelect FundSt. Louis · $250K – $2M
S2G InvestmentsChicago
S2G VenturesChicago · $1M – $5M
Able PartnersreportedNew York · $500K – $3M
AgFunderreportedSan Francisco · $10K – $5M
Cantos VenturesreportedSan Francisco · $400K – $1.5M
Digitalis VenturesreportedNew York · $100K – $10M
KdT VenturesreportedAustin · $500K – $3M
Khosla VenturesreportedMenlo Park · $5K – $50Mvia Alex Morgan · board
Reported raises · per SEC filings
Form D private placements▶$24.4MraisedJan 2026 · 35 investors · BiotechnologyRule 506(b)
▶$24.4MraisedJan 2026 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jayson DallasDirector
- Anand ParikhExecutive Officer, Director, Promoter
- Alex MorganDirector
- Robert GouldDirector
- Stephen HahnDirector
- Oliver MaddocksExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $24.4M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.